Is MaxCyte Stock a Good Investment?
MaxCyte Investment Advice | MXCT |
- Examine MaxCyte's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research MaxCyte's leadership team and their track record. Good management can help MaxCyte navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact MaxCyte's business and its evolving consumer preferences.
- Compare MaxCyte's performance and market position to its competitors. Analyze how MaxCyte is positioned in terms of product offerings, innovation, and market share.
- Check if MaxCyte pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about MaxCyte's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in MaxCyte stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if MaxCyte is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine MaxCyte Stock
Researching MaxCyte's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 71.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.74. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MaxCyte recorded a loss per share of 0.34. The entity had not issued any dividends in recent years.
To determine if MaxCyte is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding MaxCyte's research are outlined below:
| MaxCyte generated a negative expected return over the last 90 days | |
| MaxCyte has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 41.29 M. Net Loss for the year was (37.92 M) with profit before overhead, payroll, taxes, and interest of 39.16 M. | |
| MaxCyte currently holds about 240.89 M in cash with (21.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37. | |
| MaxCyte has a poor financial position based on the latest SEC disclosures | |
| Roughly 71.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: This MaxCyte Insider Increased Their Holding In The Last Year |
MaxCyte Quarterly Liabilities And Stockholders Equity |
|
MaxCyte uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in MaxCyte. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MaxCyte's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact MaxCyte's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises MaxCyte's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-08 | 2023-09-30 | -0.1 | -0.11 | -0.01 | 10 | ||
2021-09-13 | 2021-06-30 | -0.06 | -0.05 | 0.01 | 16 | ||
2024-11-07 | 2024-09-30 | -0.124 | -0.11 | 0.014 | 11 | ||
2024-03-12 | 2023-12-31 | -0.07 | -0.05 | 0.02 | 28 | ||
2023-03-15 | 2022-12-31 | -0.07 | -0.05 | 0.02 | 28 | ||
2022-11-09 | 2022-09-30 | -0.08 | -0.06 | 0.02 | 25 | ||
2021-11-10 | 2021-09-30 | -0.05 | -0.03 | 0.02 | 40 | ||
2022-05-09 | 2022-03-31 | -0.07 | -0.04 | 0.03 | 42 |
Know MaxCyte's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MaxCyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MaxCyte backward and forwards among themselves. MaxCyte's institutional investor refers to the entity that pools money to purchase MaxCyte's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Portolan Capital Management, Llc | 2024-06-30 | 1.7 M | Swedbank Ab | 2024-09-30 | 1.6 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 1.4 M | Chevy Chase Trust Holdings, Inc. | 2024-09-30 | 1.3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.2 M | Ameriprise Financial Inc | 2024-06-30 | 1.1 M | Northern Trust Corp | 2024-09-30 | 860.3 K | Silvercrest Asset Management Group Llc | 2024-06-30 | 708.2 K | Centerbook Partners Lp | 2024-09-30 | 585.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 9.3 M | Cadian Capital Management Lp | 2024-09-30 | 8.2 M |
MaxCyte's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 371.3 M.Market Cap |
|
MaxCyte's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.14) | (0.15) | |
| Return On Capital Employed | (0.19) | (0.18) | |
| Return On Assets | (0.14) | (0.15) | |
| Return On Equity | (0.16) | (0.16) |
Determining MaxCyte's profitability involves analyzing its financial statements and using various financial metrics to determine if MaxCyte is a good buy. For example, gross profit margin measures MaxCyte's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of MaxCyte's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in MaxCyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MaxCyte. Check MaxCyte's Beneish M Score to see the likelihood of MaxCyte's management manipulating its earnings.
Evaluate MaxCyte's management efficiency
MaxCyte has return on total asset (ROA) of (0.1125) % which means that it has lost $0.1125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.16) %, meaning that it created substantial loss on money invested by shareholders. MaxCyte's management efficiency ratios could be used to measure how well MaxCyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.15 in 2024. Return On Capital Employed is likely to gain to -0.18 in 2024. At this time, MaxCyte's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 19.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 9.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.25 | 2.36 | |
| Tangible Book Value Per Share | 2.25 | 2.36 | |
| Enterprise Value Over EBITDA | (10.37) | (10.89) | |
| Price Book Value Ratio | 2.09 | 2.20 | |
| Enterprise Value Multiple | (10.37) | (10.89) | |
| Price Fair Value | 2.09 | 2.20 | |
| Enterprise Value | 457.6 M | 696.4 M |
MaxCyte showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 1.16 |
Basic technical analysis of MaxCyte Stock
As of the 28th of November, MaxCyte secures the Risk Adjusted Performance of (0.05), mean deviation of 2.47, and Standard Deviation of 3.29. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MaxCyte, as well as the relationship between them.MaxCyte's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MaxCyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on MaxCyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MaxCyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MaxCyte's Outstanding Corporate Bonds
MaxCyte issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MaxCyte uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MaxCyte bonds can be classified according to their maturity, which is the date when MaxCyte has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MAY DEPT STORES Corp BondUS577778BH56 | View | |
| MAY DEPT STORES Corp BondUS577778BQ55 | View | |
| MAY DEPT STORES Corp BondUS577778CE17 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand MaxCyte's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing MaxCyte's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.16) | |||
| Mean Deviation | 2.47 | |||
| Coefficient Of Variation | (1,445) | |||
| Standard Deviation | 3.29 | |||
| Variance | 10.81 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.17) | |||
| Maximum Drawdown | 17.97 | |||
| Value At Risk | (5.75) | |||
| Potential Upside | 4.86 | |||
| Skewness | (0.52) | |||
| Kurtosis | 0.8014 |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.16) | |||
| Mean Deviation | 2.47 | |||
| Coefficient Of Variation | (1,445) | |||
| Standard Deviation | 3.29 | |||
| Variance | 10.81 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.17) | |||
| Maximum Drawdown | 17.97 | |||
| Value At Risk | (5.75) | |||
| Potential Upside | 4.86 | |||
| Skewness | (0.52) | |||
| Kurtosis | 0.8014 |
Consider MaxCyte's intraday indicators
MaxCyte intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MaxCyte stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
MaxCyte Corporate Filings
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 16th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
MaxCyte Stock media impact
Far too much social signal, news, headlines, and media speculation about MaxCyte that are available to investors today. That information is available publicly through MaxCyte media outlets and privately through word of mouth or via MaxCyte internal channels. However, regardless of the origin, that massive amount of MaxCyte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MaxCyte news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MaxCyte relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MaxCyte's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MaxCyte alpha.
MaxCyte Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards MaxCyte can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
MaxCyte Corporate Management
| James Brady | Senior Support | Profile | |
| Stark Thompson | Consultant | Profile | |
| Jill Mayer | Senior Resources | Profile | |
| Cenk Sumen | Chief Officer | Profile | |
| Douglas Doerfler | President, Founder | Profile | |
| Jay Gelfman | Senior Operations | Profile |
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.